Published in Drug Week, May 26th, 2006
"A novel oxindole was discovered as an HIV non-nucleoside reverse transcriptase inhibitor via HTS using a cell-based assay," scientists writing in the journal Bioorganic & Medicinal Chemistry Letters report.
According to T. Jiang and colleagues at Novartis Research Foundation, "Systematic structural modifications were carried out to establish its SAR. These modifications led to the identification of oxindoles with low nanomolar potency for inhibiting HIV replication."
The authors concluded, "These novel and potent oxindoles could serve as advanced leads for further...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.